Scancell hails improved survival in melanoma study as it readies for phase III

Scancell reported phase II SCOPE data showing its melanoma vaccine candidate iSCIB1+, given with ipilimumab and nivolumab, achieved 74% progression‑free survival at 16 months in a genetically defined (HLA) target group (39 of 50 patients; target HLA types cover ~80% of melanomas), versus a published 50% PFS at 11.5 months for standard therapy, with overall response rate 56%, disease control 79% and early overall survival showing a 14% improvement at 26 months. T‑cell response magnitude tracked with clinical outcomes, and the company said regulators including the FDA have been positive, agreeing on a phase III design with PFS likely as the primary endpoint. Scancell is preparing for late‑stage testing in 2026, prioritizing a needle‑free intramuscular delivery route (it has halted an intradermal arm) and is in partner/financing talks—if reproduced in a pivotal trial these results could materially challenge current checkpoint inhibitor standard of care, but confirmation in phase III is required.

Analysis

Scancell reported mid-stage SCOPE data showing its vaccine candidate iSCIB1+ combined with ipilimumab and nivolumab achieved a progression-free survival (PFS) rate of 74% at 16 months in a genetically defined HLA target group (39 of 50 patients; target HLA types represent ~80% of melanoma cases), versus a published 50% PFS at 11.5 months for the standard checkpoint inhibitor combination. The same cohort showed a 56% overall response rate and 79% disease control, with early overall survival data indicating a 14% improvement at 26 months; the magnitude of patients’ T‑cell responses correlated with clinical outcomes.

Management reports positive engagement with the FDA and other regulators, with agreement on a future phase III design and confirmation that PFS is likely to serve as the primary endpoint; the company is preparing for late-stage development in 2026, has prioritized a needle‑free intramuscular delivery route, and is in active discussions on partnering and financing. Company commentary framed the data as a potential to “redefine standard of care” and quantified a 24% PFS improvement versus standard therapy.

The data are encouraging but derive from a small, selected cohort and a cross‑trial comparison; reproducibility in a randomized phase III is the critical catalyst. Market signals are moderately positive but assign limited near‑term impact until phase III readouts and resolution of financing/partnering, so key near‑term risks are sample size, generalizability beyond the HLA subset, and funding dilution.

Key Decisions for Investors

• Consider a small, speculative position or watchlist placement to gain exposure to upside ahead of phase III while limiting position size because phase II is promising but not definitive
• Monitor regulatory milestones closely—confirmation of the phase III design, acceptance of PFS as primary endpoint, and trial start timing are de‑risking events to increase conviction
• Require phase III replication of the reported ~24% PFS improvement and OS signals before increasing exposure; until then prefer hedged positions or defined stop‑losses
• Track partner announcements and financing terms closely since partnership structure or dilution will materially affect equity value and should guide position sizing